Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

In October 2023, it signed an agreement with Diakonos Oncology to develop a cell therapy, DOC1021, to treat glioblastoma ...

As part of our Masterclass series, GP specialist in diabetes Dr Elizabeth Martin explains the key points in prevention, diagnosis and management of diabetes in general practice. This series showcases ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...

However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart ...